Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 1/20 | 0.43 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | DGAT1 | O75907 | 1/20 | 0.41 |
| ▸ | PARP15 | Q460N3 | 1/20 | 0.41 |
| ▸ | PARP10 | Q53GL7 | 1/20 | 0.41 |
| ▸ | BACE1 | P56817 | 2/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21991301 | 0.88 | CYP1A2 (0.41) | CYP1A2CYP2C9ALDH1A1DGAT1PARP15 | |
| SCHEMBL21991305 | 0.87 | DGAT1 (0.49) | CYP2C9DGAT1PARP15PARP10 | |
| SCHEMBL21991917 | 0.87 | DGAT1 (0.39) | CYP1A2CYP2C9ALDH1A1DGAT1PARP15 | |
| SCHEMBL21991947 | 0.86 | BACE1 (0.41) | PARP15PARP10BACE1 | |
| SCHEMBL21991531 | 0.79 | SSTR4 (0.53) | DGAT1 | |
| SCHEMBL3881117 | 0.79 | DGAT1 (0.49) | ALDH1A1DGAT1KDM4E | |
| SCHEMBL21991239 | 0.78 | MEN1 (0.42) | CYP1A2BACE1 | |
| SCHEMBL21991944 | 0.77 | PPARA (0.49) | CYP1A2CYP2C9DGAT1PARP15PARP10 | |
| SCHEMBL5366382 | 0.77 | HPGD (0.49) | CYP2C9ALDH1A1 | |
| SCHEMBL21748570 | 0.76 | SSTR4 (0.53) | CYP1A2ALDH1A1DGAT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220409566-A1 | CCL5 Inhibitors | LAPKO INC, dba AFECTA PHARMACEUTICALS | 2022-12-29 | — | — | US | disclosed |
| US-20220142961-A1 | CCL5 Inhibitors | LAPKO INC, dba AFECTA PHARMACEUTICALS | 2022-05-12 | — | — | US | disclosed |
| US-11318111-B2 | CCL5 inhibitors | LAPKO INC (US) | 2022-05-03 | — | — | US | disclosed |
| US-20210196665-A1 | CCL5 Inhibitors | AFECTA PHARMACEUTICALS, INC. (US) | 2021-07-01 | — | — | US | disclosed |
| US-10940132-B2 | CCL5 inhibitors | AFECTA PHARMACEUTICALS, INC. (US) | 2021-03-09 | — | — | US | disclosed |
| US-20200138766-A1 | CCL5 INHIBITORS | LAPKO INC. DBA AFECTA PHARMACEUTICALS | 2020-05-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220142961-A1 | CCL5 Inhibitors | CCL5, CCL11, CCR5 | CYP1A2 2919/4885CYP2C9 1183/4885ALDH1A1 932/4885 |
| US-20200138766-A1 | CCL5 INHIBITORS | CCL5, CCL11, CCR5 | CYP1A2 2919/4885CYP2C9 1183/4885ALDH1A1 932/4885 |
| US-20210196665-A1 | CCL5 Inhibitors | CCL5, CCL11, CCR5 | CYP1A2 2919/4885CYP2C9 1183/4885ALDH1A1 932/4885 |
| US-10940132-B2 | CCL5 inhibitors | CCL5, CCL11, CCR5 | CYP1A2 2919/4885CYP2C9 1183/4885ALDH1A1 932/4885 |
| US-11318111-B2 | CCL5 inhibitors | CCL5, CCL11, CCR5 | CYP1A2 2919/4885CYP2C9 1183/4885ALDH1A1 932/4885 |
| US-20220409566-A1 | CCL5 Inhibitors | CCL5, CCL11, CCR5 | CYP1A2 2919/4885CYP2C9 1183/4885ALDH1A1 932/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.